L3 diabetes type 1:
	- diabetes mellitus physiology:
		- 70-99mg/dl nromal range
		- post-prandial < 140mg/dl
		- dx:
			- FPG >= 126 mg/dl (fast >= 8h): more accurate
			- 2h PG >= 200 mg/dl OGTT: dxs more people, more accurate
			- A1C >= 6.5%: less accurate w/ hemoglobinopathies
			- hyperglycemia symptoms + random PG >= 200 mg/dl

		- types:
			- type 1: destruction of β-cells
			- type 2: loss of β-cell insulin secretion + insulin resistance
			- gestational diabetes: 2nd or 3rd trimester dx
			- other: monogenic diabetes syndromes, exocrine pancrease diseases, drug induced

	- diabetes type 1:
		- symptoms:
			- polydipsia
			- polyphagia
			- polyuria
			- nocturnal enuersis
			- weight loss
			- irritable
			- emesis + lethargy
		- tx:
			- always insulin!
		- epidiomiology:
			- onset: 5-7 yo and after puberty
				- 9 mo to 90 yo
			- increasing incidence
			- M:F = 1.32
			- incidence: 1:300 normal, 1:20 if 1st degree relative
		
		- risks:
			- HLA DR3/4
			- FH of autoimmunity
			- triggers: maybe viruses, nutrition, hygiene
		- pathogenesis:
			- autoreactive T cells
			- normal iselt -> insulitis (autoantibodies present) -> β-cell destruction (over diabetes)
		- dx:
			- antibodies:
				- GAD65: glutamic acid decarboxylase
				- ICA: islet cell antibodies
				- IAA: insulin autoantibodies
				- zinc transporter
		- tx:
			- prevention: teplizumab (anti-CD3) delays onset
			- 
		- course:
			- precipitating event -> normal insulin -> insulin loss/normal glucose
			- C-peptide present (overt diabetes) -> no C-peptide

	- diabetic ketoacidosis:
		- symptoms:
			- emesis + lethargy
		- physical exam:
			- tired
			- sunken eyes
			- dry mucous membranes
			- tachycardia
			- increased cap refill
			- cold extremities
		- signs:
			- kussmaul respirations
			- hyperglycemia
			- acidosis
			- acetone breath
			- ketones + glucose in urine
		- tx:
			- IV fluids
			- insulin drip

	- insulin pathways:
		- released from β-cells
		- stimulates glucose usage/uptake
			- uptake mainly in skeletal muscles
			- insulin binds insulrin receptor -> GLUT4 membrane fusion

	- insulin + blood sugar management:
		- types:
			- rapid (2h): lispro, aspart, glulisine
			- short (5h): regular
			- intermediate (12): nph
			- long acting: glargine, detemir

		- paradigm:
			- bolus + basal
			- basal:
				- always need insulin, constant dose
				- suppresses gluconeogenesis at night + between meals
			- bolus:
				- 15 mins preprandial
				- needed for all carbs
				- dose ~ f(PG, carb load)
		- limits:
			- subq not rapid enough for SUGARY stuff
			- insulin irreversible -> hypoglycemic risk
			- expensive

		- check PG:
			- before meals, bed, driving
			- pre/post exercise
			- 6-10x per day

		- pumps:
			- microdoses (.025 units)
			- uses rapid insulin analogs
			- enter PG + carb load -> gives bolus
			- pump failure -> DKA
			- hypoglycemia

		- pump + glucose sensor:

L4:
	- β-cell physiology:
		- high glucose -> into β-cell by GLUT2 receptor -> increased ATP/ADP
		- increased ATP/ADP -> closes K+ channels -> Ca+ wave -> exocytosis of insulin
	
	- β-cell pathophysiology:
		- hyperglycemia -> increased ROS -> islet inflammation + death
		- increased free fatty acids -> increased endoplasmic reticulum stress
		- high fat diet -> impaired GLUT2 receptors
		- amyloid plaques in islets
		- lower β-cell mass -> higher T2DM risk with increased BMI

	- insulin resistance:
		- insulin binds insulin receptor (tyrosine kinase) -> GLUT4 bind with membrane
		- IR or GLUT4 muts -> insulin resistance
		- chronic inflammation -> decreased GLUT4 release

	- hypertrophic adipose:
		- with insulin stimulation:
			- reduced: glucose uptake, triglyercide synthesis
			- increased: FFA release, hypoxia, inflammation

	- microbiome:
		- gut inflammation -> insulin resistance
	
	- DM liver:
		- proinflammation + oxidative stress:
			- impaired glycogen synthesis
			- unsuppressed gluconeogenesis
			- pro-inflammatory proteins (CRP)
			- increased lipogenesis
		- increased glucagon in T2DM -> gluconeogenesis

	- diabetes type II:
		- epidiomiology:
			- 90% of DM cases
			- 15% increase risk of death
			- 2x med costs
			- 60% risk for early death

		- screening:
			- overweight
			- 1st degree relative w/ DM
			- high risk:
				- HTN, TG > 250, HDL < 35
				- PCOS
				- race: non white
			- pre-diabetes: every year
			- women with hx of gestational diabetes - 3y
			- HIV ART: yearly
			- rest: at age 35, every 3 years

		- risks:
			- monogenic:
				- maturity onset diabetes of the young (MODY)
				- 1-4% incidence
			- polygenic: 90% twins, 40% have >= 1 parent w/ T2DM

		- pathophysiology:
			- reduced insulin secretion
			- insulin resistance
			- increased gluconeogenesis

		- symptoms:
			- acanthosis nigricans

		- prevention:
			- lifestyle:
				- 7% weight loss, 150 mins/week activity
				- 58% reduction
			- metformin:
				- consider for pre-diabetes + high BMI + <60yo + gestational DM
				- 31% reduction
			- bariatric surgery: 78% reduction

	- gestational diabetes:
		- pregnant person develops diabetes in 2nd or 3rd trimester
		- screening:
			- high risk: 1st trimester
			- routine: 24-28 week w/ OGTT
		- 2nd + 3rd trimester:
			- increased GH, prolactin, lactogen, CRH, and progesterone
			- increase IR
		- risks:
			- preeclampsia
			- macrosomia
			- delivery issues
			- neonatal respiratory + metabolic issues
			- T2DM: 50% of gestational

	- drug induced diabetes:
		- medications:
			- glucocorticoids
			- immunosuppressants
			- statins

	- exocrine pancreas diseases:
		- cystic fibrosis:
			- mucous overproduction -> β-cell destruction
			- presents as combo of T1DM + T2Dm
			- treat with only insulin

		- hemochromatosis: iron overload -> β-cell dysfunction + insulin resistance
		- chronic pancreatitis: glucose intolerance -> diabetes in late stages

	- pancreatic cancer: 80% present with new onset T2DM



L5 DM complications:

	- diabetic ketoacidosis (DKA):
		- absolute or relative insulin deficiency
		- signs:
			- triad:
				- hyperglycemia
				- ketonemia
				- anion gap metabolic acidosis
					- pH < 7.3, anion gap > 10, bicarb < 18
		- symptoms:
			- rapid onset
			- hyperglycemia: polyuria, polydipsia, blurred vision
			- dehydration: dizziness, dry mucosa, tachycardic, hypotensive
			- acidosis:
				- kussmaul breathing, fruity breath
				- nausea, vomitting, abdominal pain
			- hyperosmolarity:
				- lethargy -> coma

		- precipitating factors:
			- infection
			- insulin omission
			- T1DM onset
			- drugs: glucocorticoids, atypical antipsychotics, cocaine,
			- GI illness: pancreatitis
			- other: MI, pregnancy

		- pathophysiology:
			- insulin deficiency
			- counter hormones (glucagon, cortisol) -> glycogenolysis, gluconeogenesis + lipolysis
			- hyperglycemia -> osmotic diuresis -> electrolyte loss -> volume depletion, decreased GFR -> worse hyperglycemia

		- tx:
			- IV fluids
			- correct electrolytes
			- correct acidosis/hyperglycemia with insulin

	- hyperosmolar hyperglycemic state (HHS):
		- DKA w/o acidosis
		- signs:
			- hyperglycemia: often >600mg/dl
			- hyperosmolarity: >320 mOsmol/kg
			- serum pH > 7.3
			- absent/mild ketones


	- hypoglycemia:
		- PG < 55mg/dl
		- whipple's triad: hypoglycemic symptoms + low PG + fixing PG fixes symptoms
		- physiology:
			- counterregulatory:
				- decrease insulin
				- increase glucagon
				- increase epi -> increase gluconeogenesis
				- increase cortisol + GH -> increase gluconeogenesis + IR
		- symptoms:
			- autonomic: palpitations, tremor, anxiety
			- neuroglycopenic symptoms: dizziness, confusion, weakness

		- tx:
			- oral 15g glucose/dextrose or 1mg glucagon
			- 25-50ml of 50% dextrose + water

	- diabetes mellitus complications:
		- pathophysiology:
			- increased polyol pathway:
				- hyperglycemia -> saturates hexokinase -> increased polyol pathway -> reduced NADPH/NAD+
				- reduced NADPH/NAD+ -> reduced glutathione synthesis -> icnreased ROS
			- advanced glycosylation end products (AGEs):
				- hyperglycemia -> glycolsulation of proteins -> AGEs
				- AGES effect:
					- gene transcription
					- increased cytokines + growth factors -> vascular damage
					- cell dysfunction
			- activated protein kinase C (PKC):
				- increased NF-kB, ROS, PAL-1, TGF-B, VEGF
				- decreased eNOS

		- types:
			- miscrovascular:
				- retinopathy:
					- epidiomiology: 85% at 20 years
					- classifications:
						- non-proliferative: no new vessel
							- exudates
							- microaneurysms
							- hemorrhage
						- proliferative: new vessels
							- neovascularization
						- macular edema: retinal thickening + macular edema
					- tx:
						- anti-VEGF occular injections
						- laser ablation
						- vitrectomy: tiny cuts -> remove blood

				- neuropathy:
					- epidiomiology: 40% at 10 years
					- types:
						- autonomic:
							- causes significant mortality risk
							- symptoms:
								- cardio: tachycardiam, orthostatic hypotension, silent ischemia, sudden death: ventricular arrhythmias

								- GI: GERD, gastroperesis, enteropathy, colonic hypomotility								
						- distal symmetric polyneuropathy:
							- 75% of diabetic neuropathy
							- large fibers:
								- myelinated
								- loss of protective sensation
								- proprioception loss
									- poor balance
									- decreased vibration sense
									- decreased ankle reflex
								- leads to ulcers, callus, + amputations

							- small fibers:
								- no myelin
								- symptoms:
									- dysesthesias: burning pain
									- hyperalgesia: exaggerated pain
									- allodynia: pain on painless contact
									- paresthesia
									- decreased thermal discrimination
				
				- nephropathy:
					- epidiomiology:
						- < 40% of DM
						- 40% of people on dialysis have DM nephropathy
					- course:
						- stages:
							- early: hyperfiltration: increased GFR -> thickened GBM + mesangial expansion
							- microalbuminuria: Ualbumin 30-300mg
							- macroalbuminuria: Ualbumin >300mg, decreased GFR + increased BP
							- ESRD: uremia -> HD/transplant
					- prevention:
						- lifestyle mods
						- tight PG control: SGLT-2i + GLP-1 agonists
						- hypertension control
						- ACEi/ARBs for htx or macroalbuminuria

			- macrovascular:
				- CVD: 2-4x OR
					- heart: angina, MI
					- peripheral: claudication, ulceration, gangrene
					- cerebral: TIA, stroke
				- skin manifestations
					- 80% of diabetes
					- types:
						- infections
						- xerosis
						- inflammatory: necrobiosis lipoidica

L6: treatment of DM:
	- medications:
		- metformin:
			- cheap
			- weight neutral (sometimes loss)
			- low hypoglycemia risk
			- 1.5% A1C decrease
			- contraindicated:
				- renal insufficiency
				- metabolic acidosis
				- alcoholism, age > 80
				- unstable CHF, COPD
		- 
	- treatment paradigm:
		- 1st: metformin
		- 




L7: obesity:
	- epidiomiology:
		- 73% US overweight, 43% obese

	- BMI heritability ~ 70%
	- MC4R defiency:
		- hyperphagia, obesity
		- increased BMD
		- increased linear growth
		- hyperinsulinemia

	- weight regulation pathophysiology:
		- NPY/AgRP neuron: increase appetite
			- stimulated by ghrelin
			- inhibited by GLP-1, PYY, leptin, insulin
		- POMC neuron: decrease appetite
			- stimulated by leptin, insulin

		- sleep loss -> increased cortisol -> increased appetite

	- ACEs increase obesity risk
	
	- weight gain meds:
		- CCB (DHB)
		- anti-diabetics: insulin, sulfonylureas, TZDs

	- high BMI -> diabetes risk

	- BMI:
		- classifications:
			- <18.5: underweight
			- 18.5-25: normal
			- 25-30: overweight
			- 30-35: obesity I
			- 35-40: obesity II
			- >= 40: obesity III

	- tx:
		- paradigm:
			- lifestyle mods + health coaching:
				- all
			- pharmocatherapy
				- obese I-III
				- short term:
					- phentermine:
						- noradrenergic -> stimulates POMC
					- diethypropion
				- long term:
					- metformin: increased insulin glc uptake
					- phentermine-topiramate:
						- noradrenergic + inhibits NPY/AgRP -> decreased appetite
						- teratogenic, glaucoma, renal stones
					- naltrexone-bupropion:
						- µ opioid blocker -> stops auto-inhibition of POMC -> decreased appetite
					- orlistat:
						- inhibits lipases -> fat malabsorption
					- GLP-1 agonists (liraglutide, semaglutide):
						- stimulates POMC
						- inhibits NPY/AgRP
						- increased post-prandial insulin
						- delayed gastric emptying

			- devices / endoscopic:
				- overweight/obese I-III
				- cellulose hydrogel: increase volume -> satiety, 6% loss in 6mos
				- intragastric balloons: 15% loss at 6mos (removal), 8% loss at 12mos

				- endoscopic sleeve gastroplasty:
					- staple stomach in spots
					- 20% loss at 2 years
			- bariatric surgery:
				- obesity III
				- types:
					- gastric band: 15%
					- sleeve gastrectomy: 20%
					- roux-en-y gastric bypass: 30%
	
	- hormones:
		- ghrelin: from stomach -> causes hunger
		- PYY:
			- from ileum + colon -> delays gastric emptying
			- post-prandial satiety factor

L8: nutrition:
	- 




































L27: calcium phosphate metabolism:
	- skeleton:
		- RANK system:
			- RANKL: released by osteoblasts
			- RANK: on pre-osteoclasts -> osteoclasts mature + activity
			- OPG: RANKL decoy
				- estrogen -> OPG -| RANKL (low estrong -> osteoclast activity)

	- calcium homeostasis:
		- range:  8.5-10.2 mg/dl
		- plasma compartments:
			- ionized (50%)
			- protein bound (40%)
			- complexed (10%)

		- compartment shifters:
			- albumin: changes total calcium, no effect on ionized
				- correct total ca = total_calcium + 0.8 * (4.0 - serum_albumin)
			- acid-base: more acidic (lower pH) -> higher ionized, total calcium same
			- anion concentration (phosphate + sulfate): higher phos -> lower ionized, total calcium same
			- if acid-base imbalance or PO4 change (ESRD) -> measure ionized calcium directly

		- calcium homeostasis:
			- GI absorption:
				- duodenum + upper jejunum
				- active: TRPV6 (importer) -> calbindin -> PMCA (extruder)
					- calcitriol -> increased TRPV6 + PMCA 
				- passive (main source)
			
			- bone remodeling:
				- PTH + calcitriol -> increased bone resorption
				- calcitonin -> decreases bone resorption

			- renal:
				- normal calciuria: 100-300 mg/day
				- passive reabsorption: 60% in PT + 30% in TAL
				- active: 9% in DT
					- TRPV5 (importer) -> calbindin -> NCX/PMCA
						- upregulated by calcitriol + PTH

			- PTH:
				- CaSR (g protein) -> arachidonic acid prodcution -| PTH secretion
				- PTH receptor: g protein -> adenylate cyclase -> cAMP -> PKA etc

				- targets (increases calcium):
					- intestine (indirect):
						- PTH -> renal 1α-hydroxylase -> calcitriol -> calcium absorption
					- kidney:
						- PTH -> renal 1α-hydroxylase -> calcitriol 
						- PTH -> TRPV5 + NCX + PMCA + calbindin
						- PTH -> increases lumen charge -> increased passive absorption
					
					- skeleton:
						- PTH (osteoblast receptor) -> increase RANKL and decreases OPG

			- vitamin D:
				- D3: cholecalciferol
				- calcitriol binds VDR, complexes with RXR (retinoid X receptor) -> transcription
				- synthesis:
					- if calcium high -> make 24,25(OH)2D
					- if low -> make calcitriol (1,25(OH)2D)

				- 1α-hydroxylase control:
					- PTH increases production
					- low calcium -> increased PTH -> increased production
					- FGF-23 -| 1α-hydroxylase + activates 24α-hydroxylase
					- calcitriol (negative feedback):
						- binds parathyroid receptors -> decreases PTH
						- increases 24α-hydroxylase
						- inhibits 1α-hydroxylase

				- calcitriol targets (increases serum calcium):
					- GI: increases TRPV6 + PMCA
					- skeleton: increases bone resorption
					- renal: increases TRPV5 + calbindin

			- calcitonin:
				- parafollicular C cells of thyroid -> secretory granules
				- actions:
					- skeleton: inhibits osteoclasts/resorption
					- renal: increases calciuria
				- used as hypercalcemia + osteoporosis therapy


	- phosphate homestasis:
		- GI absorbtion:
			- jejunum
			- active: NPT2b (increased by calcitriol)
			- passive: unregulated

		- skeleton:
			- PTH + FGF-23 increase resorption

		- renal:
			- reabsortpion: 90% in PT + 10% excreted
			- NaPi-IIa/NaPi-IIc/PIT-2 (importers)
				- PTH + FGF-23 control trafficking
				- calcitriol -> NaPi expression?

		- phosphate:
			- low phosphate -> increases NaPi-IIa -> increases PO4 reabsorption

		- PTH (overall decreases PO4):
			- GI: PTH -> calcitriol -> increase PO4 reabsorption
			- skeleton: PTH -> bone resorption
			- renal:
				- PTH -> decreased NaPO4 cotransporter -> decreased PO4 reabsorption
			- high PTH: renal dominates -> low PO4

		- FGF-23 (decreases PO4):
			- "phosphatonin"
			- secreted by osteoblasts/cytes
			- effects:
				- increases PO4 excretion
				- decrease 1α-hydroxylase -> decreased calcitriol -> decreased GI PO4 absorption
			- states:
				- high FGF-23: hypophosphatemia, osteomalacia, muscle weakness
				- low FGF-23: hyperphosphatemia, soft tissue calcification
			- renal failure -> reduced PO4 filtration -> increased FGF-23 to lower PO4

		- calcitriol (raises PO4):
			- GI: increased phosphate absorption
			- skeletal: calcitriol -> bone resorption
			- renal: increased reabsorption



L26: hypo/hypercalcemia:
	- calcium regulation:
		- low Ca -> activate CaSRs in parathyroid
		- CaSR activation -> PTH release
			- bone resorption -> increased calcium + phosphate
			- calcidiol (kidneys) -> calcitriol -> increased calcium + phosphate GI absorption
			- kidney: increased reabsorption calcium + decreased phosphate reabsorption


	- hypercalcemia:
		- symptoms:
			- fatigue -> concentration -> confusion -> death
			- GI: anorexia, nausea/vomiting, constipation, pancreatitis
			- nephrogenic DI, dehydration, renal insufficiency, nephrolithiasis
			- MSK: weakness, hyporeflexia, bone pain/fractures
			- cardio: short QT interval, bradycardia, cardiac arrest
		- pathophysiology:
			- feedback: hypercalcemia -> nephrogenic DI -> dehydration + reduced fluid intake -> worse hypercalcemia
		- tx:
			- paradigm:
				- Ca < 12 mg/dl: avoid thiazisdes, lithium, volume depletion, etc
				- 12-14 mg/dl: treat if symptomatic
				- >14 mg/dl: treat
			- lower calcium:
				- IV saline
				- possible lasix
				- calcitonin:
					- osteoclast inhibitor
					- calcuretic
					- rapid but tachiphylactic
				- bisphosphonate: only IV -> zoledronate (preferred), pamidronate
				- glucocorticoids: reduced GI calcium absorption
				- denosumab: if refractory to bisphosphonates
				- dialysis
				- cinacalcet: for parathryoid cancer
		- causes:
			- primary hyperparathyroidism (55%):
				- excessive production by 1+ nodes
				- epidiomiology:
					- 1/1,000
					-  3:1 women to men
					- early post menopause (50s)
				- pathophysiology:
					- shifted PTH set point
					- loss of corticol bone (affects radius > lumbar)
				- symptoms:
					- "not sick"
					- 80% asymptomatic
					- classic: osteitis fibrosa cystica, nephrolithiasis, hypercalciuria
				- dx:
					- high serum calcium + normal/high PTH
					- low calcidiol + high/normal calcitriol
				- tx:
					- parathyroidectomy
					- surgery if:
						- stones or bone disease
						- hypercalcemia | hypercalciuria
						- reduced eGFR
						- <50 yo

			- malignancy (35%):
				- dx: low/no PTH
				- causes:
					- humoral hypercalcemia of malignancy (HHM) (80%):
						- squamous cell, renal, bladder, etc
						- PTHrP:
							- normal function: ca to breast milk, embryogenesis + development, paracrine
							- binds PTH1 receptor
							- does not increase 1-α-hydroxylase

					- osteolytic metatases (20%):
						- breast cancer, multiple myeloma
						- pathophysiology:
							- inflammation (IL-6, local PTHrP, M-CSF) -> increased osteoclast acivity
							- increase RANKL + decrease OPG
							- cycle: bone resorption -> cancer growth -> more bone resorption

					- calcitriol prodution by tumor:
						- lymphoma
						- calcitriol -> increased GI absorption -> hypercalcemia
			- other:
				- increased GI absorption: vitamin D intoxication, granulomatous disorders
				- other: pheochromocytoma, rhabdomyolysis, theophylline

	- hypocalcemia:
		- symptoms:
			- paresthesias
			- perioral/acral numbness
			- altered mental status
			- seizures
			- laryngospasms / bronchospasms
			- death
		- signs:
			- chvostek's: facial twitch
			- trouseau's: carpopedal spasm
			- cardiac: bradycardia, CHF, prolonged QT, arrythmia
		- causes:
			- high PTH:
				- vitamin D defiency | vitamin D metabolic issue (ESRD)
				- PTH resistance: hypomagnesemia
				- calcium loss: ESRD/hyperphosphatemia, pancreatitis
				- drugs: impaired skeletal calcium release: bisphosphonates, etc 
			
			- low PTH (hypoparathyroidism):
				- dx:
					- hypocalcemia >= 2 occasion >= 2 weeks apart
					- low/no PTH

				- causes:
					- destruction: surgery, autoimmune, malignancy, etc
					- hypoparathyroidism: hypo/hypermagnesemia (cisplatin, alcoholism, diuretics), CaSR mut
					- genetic: digeorge's, etc
			- renal failure
			- pancreatitis:
		- tx:
			- paradigm:
				- plan:
					- give bolus calcium
					- give IV drip
					- start oral maintenance: overlap with IV drips
				
				- confounders:
					- hypomagnesemia: correct mg first then calcium
					- acidosis: correct calcium first then pH
				- give IV calcium:
					- symptomatic hypocalcemia: treat
					- prolonged QT (always)
					- serum calcium <= 7.5 mg/dl
					- chronic hypocalcemia + unable to take PO calcium
					- seizure history

			- bolus calcium gluconate (1-2 amps):
				- give over >= 15 mins, else cardiac arrest
				- only lasts 2 hours

			- IV calcium gluconate drip:
				- 11 amps over 6-8 hours
				- dilute with D5W
					- prevents vein irritation
				- correct calcium then acidosis
				- monitor EKG if relevent/on digoxin

			- maintenance:
				- oral citrate or carbonate (needs food/acid)
				- oral vitamin D:
					- parent D
					- if unable to make calcitriol: give rocaltrol (calcitriol)
				- thiazides: control hypercalciuria -> prevent stones
				- PTH therapy:
					- natpara: helps reduce calcitriol + calcium maintenance doses
					- teriparatide
					- transcon PTH: better than natpara
					- recombinant PTH: inadequate control of calcium


L27: osteoporosis and bone diseases:
	- osteoporosis:
		- epidiomiology:
			- lifetime risks: 23% women + 7% men
			- risks:
				- age
				- fracture hx
				- gender / menopausal status
				- low BMI
				- low diet Ca + D
				- parental hx of hip fractures

		- pathophysiology:
			- small increase in BMD (6%) -> reduced large fracture risk (V66%, H40%)
			- steroids: decreased BMD
				- Ca++: increased excretion + reduced absorption
				- decreased osteoblast count
				- decreased LH/FSH -> decreased sex steroids -> decreased BMD
			- osteoblast activity:
				- slerostin -> inhibited WNT/β-catenin signaling -> reduced osteoblast activity
				- osteoblast activity -> bone formation + osteoprotegrin (OPG) release -> RANKLr decoy
		- screening:
			- women >= 65 or men >= 70
			- risks (fracture, RA, steroids): start at 50-59

		- dx:
			- fracture risk algorithm FRAX:
				- DXA + age + BMI + ethnicity + prior falls + etc
				- treat if: major fracture risk >20% or hip fracture risk >3%
			- vertebral fracture assessment (VFA):
				- use: if height loss > 1.5 inches
			- dual energy x-ray absorptiometry (DXA) scan:
			 	- osteopenia: T-score <= -1.0
			 	- osteoporosis: T-score <= -2.5 or prior hip/spine fracture
		- tx:
			- lifestyle:
				- increase exercise
				- smoking cessation
				- reduce alcohol
				- keep BMI > 20
				- minimize steroids

			- calcium + vitamin D:
				- prevention is controversial
				- recommend:
					- total calcium: 1000-1500
					- vitamin D: 1000-1200 IU/d
			- anti-resorptive:
				- estrogen:
					- increase BMD + decrease fractures
					- high TE risk
				- selective estrogen receptor modulator SERM (raloxifene):
					- agonist at bone: only at vertebra
					- antagonist at breast: decreases breast cancer risk + increases TE risk
				- bisphosphonates:
					- binds hydroxyapatite -> engulfed by osteoclast -> inhibits mevalonate pathawy -> inhibits osteoclast
					- use:
						- increases BMD: plateau at 3-4 yrs
						- largest BMD increase: trabecular sites (highest turnover)
						- antifracture effects: persists 3-5 yrs after stopping
					- types:
						- zoledronic acid: IV, best
						- alendronate
					- risks:
						- only use eGFR > 30 ml/mn
						- upper GI symptoms: sit upright for 30 mins postdose
						- zoledronate: 2-3 days flu-like symptoms first dose
						- if vitamin D defienct -> hypocalcemia
				- denosumab:
					- anti-RANKL
					- increases BMD: no plateau at 10 yrs
					- use:
						- correct vitamin D defiency first
						- subq q6mo
						- eGFR < 30: hypocalcemia risk

			- anabolic:
				- rebound effect on stopping -> taper with anti-resorptive
				- paratides (teriparatide + abaloparatide):
					- PTH analog -> activate PTH1R -> PKA/C -> osteoblast activity
					- risks:
						- osteosarcoma (2 yr limit)
						- teriparatide: mild transient postdose hypercalcemia
						- abaloparatide: nausea, headache, palpitations
				- romosozumab:
					- anti-sclerostin
					- best anabolic
					- risks: MI + stroke

	- osteomalacia:
		- characteristics:
			- reduced bone mineralization
			- extra osteoid
		- symptoms:
			- diffuse dull bone pain
			- tenderness + muscle weakness
			- waddling gait
			- minimal trauma -> fractures
		- rickets:
			- pediatric form: defective mineralization at epiphyseal growth plates
			- signs:
				- widened long bone ends
				- knees: bowed + fragile
		- dx: x-ray -> blurring + deformity
		- causes: vitamin D defiency
	
	- chronic kidney disasee - metabolic bone disease (CKD-MBD):
		- characteristics:
		- pathophysiology:
			- CKD -> increased phosphate -> increased FGF-23 (lowers phos) -> decreased calcitriol
			- increased phosphate + decreased calcitriol -> decreased calcium -> increased PTH
			- increased PTH -> bone erosion
		- types:
			- osteitis fibrosa cystica: ↑ turnover, excess PTH
			- osteomalacia: ↓ mineralization
			- adynamic bone disease: ↓ turnover
				- excessive PTH suppression tx (calcitriol) -> low PTH -> adynamic
				- tx: backoff calcitriol
			- mixed bone disease: ↑ turnover, 
	
	- paget's disease:
		- characteristics:
			- focal accelerated bone remodeling
			- lytic + osteoblastic lesions
		- symptoms: asymptomatic or pain/deformities
		- dx: elevated alkaline phosphatase or X-ray
		- tx:
			- bisphophonate
			- monitor alkaline phosphatase

	- osteogenesis imperfecta:
		- characteristics:
			- inherited brittle bones
			- minimal trauma -> fractures
		- pathogenesis: muts in type 1 collagen
		- signs: blue sclera
		- tx: bisphosphonates
























